Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: Modeling analysis

Current Medical Research and Opinion

Volumn 25, Issue 5, 2009, Pages 1273-1284

  Tunis, Sandra L ^a   Minshall, Michael E ^b   Conner, Christopher ^c   McCormick, John I ^d   Kapor, Jovana ^e   Yale, Jean François ^f   Groleau, Danielle ^e  

^a IMS Consulting Services   (United States)

^b IQVIA   (United States)

^c NOVO NORDISK INC   (United States)

^d McKesson Canada   (Canada)

^e NOVO NORDISK A S   (Denmark)

^f MCGILL UNIVERSITY   (Canada)

Author keywords

Canada; Cost effectiveness; Detemir; Hypoglycemia; NPH; Type 1 diabetes; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; INSULIN DETEMIR; ISOPHANE INSULIN;

ADULT; CALCULATION; CANADA; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG USE; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MODEL; MONEY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS;

ADULT; CANADA; COST-BENEFIT ANALYSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INCIDENCE; INSULIN; INSULIN, NPH; LIFE EXPECTANCY; MALE; MIDDLE AGED; MODELS, ECONOMETRIC; QUALITY OF LIFE; SINGLE-PAYER SYSTEM;

EID: 67649407412     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990902869169     Document Type: Conference Paper

References (54)

1. Health Canada. Diabetes in Canada, 2nd Edition. Health Canada 2002. Available at: URL: http://www.phac.aspc.gc.ca/publicat/dic-dac2/pdf/dic-dac2-en. pdf
2. Roper NA, Bilous RW, Kelly WF, et al. Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study. Br Med J 2001;322:1389-1393 (Pubitemid 32523292)
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. N Engl J Med 1993;329:977-986
4. The UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865
5. Canadian Diabetes Association. 2003 Clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003;27:i-S140
6. Hirsh IB. Insulin analogues. N Engl J Med 2005;352:174-183 (Pubitemid 40096614)
7. Hauber A, Gale EAM. The market in diabetes. Diabetologia 2006;49:247-252 (Pubitemid 43185392)
8. Current Utilization of Insulin Products in Canada. Current Utilization and Practice Analysis. Canadian Optimal Medication Prescribing and Utilization Service (COMPUS), 2008
9. An Economic Evaluation of Insulin Analogues for the Treatment of Patients with Type 1 and Type 2 Diabetes Mellitus in Canada. Canadian Optimal Medication Prescribing and Utilization Service (COMPUS);2008
10. Palmer AJ, Roze S, Valentine WJ, et al. Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials. Curr Med Res Opin 2004;20:1729-1746 (Pubitemid 39611932)
11. Valentine W, Palmer AJ, Erney-Albrecht KM, et al. Costeffectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPH. Adv Ther 2006;23:191-207 (Pubitemid 43876664)
12. Brixner DI, McAdam-Marx C. Cost-effectiveness of insulin analogs. Am J Manage Care 2008;14:766-775
13. Palmer AJ, Roze S, Valentine WJ, et al. Deleterious effects of increased body weight associated with intensive insulin therapy for type 1 diabetes: increased blood pressure and worsened lipid profile partially negate improvements in life expectancy. Curr Med Res Opin 2004;20:S67-73 (Pubitemid 39349910)
14. Currie CJ, Morgan CLI, Poole CD, et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2008;22:1523-34
15. National Institute for Clinical Excellence (NICE). Guidance on the Use of Long-Acting Insulin Analogues for the Treatment of Diabetes - Insulin Glargine. 2002 Jan 12. Technology Appraisal Guidance - No. 53
16. Rosenstock J, Davies M, Home PD, et al. A randomized, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetologia 2008;51:408-416
17. Fritsche A, Haring H. At last, a weight neutral insulin. Int J Obes 2004;28:S41-46 (Pubitemid 39389606)
18. Bartley P, Bogoev M, Larsen J, Philotheou A. Long-term efficacy and safety of insulin detemir compared to neutral protamine Hagedorn insulin in patients with type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabetic Med 2008;25:442-449
19. Home P, Bartley P, Russell-Jones D, et al. Insulin detemir offers improved glycemic control compared to NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 2004;27:1081-1087 (Pubitemid 38579770)
20. Meneghini L, Koenen C, Weng W, Selam J-L. The usage of a simplified self-titration dosing guideline (303 algorithm) for insulin detemir in patients with type 2 diabetes - results of the randomized, controlled PREDICTIVETM 303 study. Diabetes Obes Metab 2007;9:902-913 (Pubitemid 47555212)
21. American Diabetes Association Consensus PanelGuidelines for computer modeling of diabetes and its complications. Diabetes Care 2004;27:2262-2265
22. Palmer AJ, Roze S, Valentine WJ, et al. The CORE diabetes model: projecting long term clinical outcomes, costs and costeffectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision making. Curr Med Res Opin 2004;20:5-26 (Pubitemid 39349905)
23. Palmer AJ, Roze S, Valentine WJ et al. Validation of the CORE diabetes model against epidemiological and clinical studies. Curr Med Res Opin 2004;20:27-40 (Pubitemid 39349906)
24. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653
25. Visible Minority Population, by Age Group (2001 Census). Statistics Canada, 2005
26. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey (NHANES). U.S. Department of Health and Human Services 2000
27. O'Reilly D, Hopkins R, Blackhouse G, et al. Development of an Ontario Diabetes Economic Model (ODEM) and Application to a Multidisciplinary Primary Care Diabetes Management Program. Hamilton, Ontario, Canada: Program for Assessment of Technology in Health (PATH), 2006
28. Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82:2-9N (Pubitemid 28507114)
29. Phillips SJ, Whisnant JP, O'Fallon WM, et al. Prevalence of cardiovascular disease and diabetes mellitus in residents of Rochester, Minnesota. Mayo Clin Proc 1990;65:344-359 (Pubitemid 20124303)
30. Harris MI. Health care and health status and outcomes for patients with type 2 diabetes. Diabetes Care 2000;23:754-758 (Pubitemid 30414188)
31. Moss SE, Klein R, Klein BE. The prevalence and incidence of lower extremity amputation in a diabetic population. Arch Intern Med 1992;152:610-616
32. Brändle M, Zhou H, Smith BR et al. The direct medical cost of type 2 diabetes. Diabetes Care 2003;26:2300-2304 (Pubitemid 36993316)
33. Nova Scotia Pharmacy: Annual Pricing, 2007
34. Nova Scotia Pharmacy: Pricing with a 30-day Supply Assumption, 2007
35. Nova Scotia. Nova Scotia Optometrist Fees. Nova Scotia, 2007
36. Nova Scotia. Nova Scotia Podiatrist Fees. Nova Scotia, 2007
37. Coyle D, Palmer A, Tam R. Economic evaluation of pioglitazone hydrochloride in the management of type 2 diabetes mellitus in Canada. Pharmacoeconomics 2003;20:31-42
38. O'Brien JA, Patrick AR, Caro JJ. Cost of managing complications resulting from type 2 diabetes mellitus in Canada. BMC Health Serv Res 2003;3:7 (Pubitemid 38809140)
39. Ray JA, Valentine WJ, Secnik K, et al. Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain. Curr Med Res Opin 2005;21:1617-1629 (Pubitemid 41505028)
40. Alberta Physician Fee Schedule. Alberta Physician Fee Schedule. Province of Alberta, Ministry of Health 2004. Available at: URL: http://www.web.ab.ca/ pdfs/providers/WCB-Fee-Schedule-Alberta-Physicians.pdf
41. Manns B, Johnson JA, Taub K et al. Quality of life in patients with end-stage renal disease over time: the impact of dialysis modality and other important determinants. Edmonton, Alberta, Canada: Institute of Pharmaco-Economics, 2002. Report No. 02-05
42. Manns B, Tonelli M, Shrive F et al. Sevelamer in patients with end-stage renal disease: a systematic review and economic evaluation. Canadian Agency for Drugs and Technologies in Health, 2006
43. Health Costing in Alberta: 2006 Annual Report. Edmonton, Alberta, Canada: Alberta Health and Wellness, 2008
44. Caro J, Migliaccio-Walle K, Ishak KJ, et al. The morbidity and mortality following a diagnosis of peripheral arterial disease: long-term follow-up of a large database. BMC Cardiovasc Disord 2005;5:14 (Pubitemid 41460664)
45. Royal Bank of Canada, 2007. Bank of Canada, Inflation Calculator, 2008. Available at: URL: http://www.bankofcanada.ca/en/rates/inflation-calc.html
46. Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the Economic Evaluation of Health Technologies: Canada, 3rd edn. Ottawa, Ontario, Canada: CADTH Publications, 2006
47. Halpern EF, Weinstein MC, Hunink MG, et al. Representing both first- and second-order uncertainties by Monte Carlo simulation for groups of patients. Med Dec Making 2000;20:314-322 (Pubitemid 30470727)
48. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992;146:473-481
49. Leiter LA, Yale J-F, Chaisson J-L. Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia management. Can J Diabetes 2005;29:186-192 (Pubitemid 43741134)
50. Frier BM. How hypoglycaemia can affect the life of a person with diabetes. Diabetes Metab Res Rev 2008;24:87-92 (Pubitemid 351284751)
51. Wild D, von Maltzahn R, Brohan E, et al. A critical review of the literature on fear of hypoglycaemia in diabetes: implications for diabetes management and patient education. Patient Educ Counsel 2007;68:10-15 (Pubitemid 47126791)
52. The Action to Control Cardiovascular Risk in Diabetes Study GroupEffects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559
53. The ADVANCE Collaborative GroupIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572
54. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials. Diabetes Care 2009;32:187-192